Overview of Granules India Limited

• https://www.granulesindia.com/
• Headquarters: Hyderabad, India
• Founded: 1984

Granules India Limited is focusing on vertically integrated pharmaceutical companies in India. Granules manufacture Active Pharmaceutical Integrated(API), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), distributed to quality-conscious customers in both regulated and semi-regulated markets. Granules India Limited in manufacturing, quality, and customer service.

The Core business of Granules India Limited has a strong presence in ‘first line of defense products, including Paracetamol, Ibuprofen, Guaifenesin, and Metformin. Our integrated model for manufacturing APIs, PFIs, and Finished Dosages enables us to provide products across the value chain and enhances our competitiveness. Granules India Limited has emerged into a knowledge-driven, R&D-focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

• Granules Consumer Health (GCH)
  • GCH, our consumer health division, was established to leverage our efficiencies, scale, integration, and relationship management for our core products as well as other large-volume pharmaceutical products.

Granules India Limited Product

1. Active Pharmaceutical Integrated(API),
2. Pharmaceutical Formulation Intermediates (PFIs), and
3. Finished Dosages (FDs),

1. Active Pharmaceutical Integrated(API)

API on efficiently creating high-quality APIs in key therapeutic categories. API portfolio has made it possible for us to emerge as one of the most efficient and cost-effective manufacturers, globally. The R&D team has developed and commercialized several products. Such product categories include anti- retrovirals, anti- hypertensives, anti-histamines, anti- infectives, analgesics, anti-coagulants, anti-fibriotics and platelet inhibitors.

API installed capacity of 26,360 TPA in the Core business, 283 KL in the Emerging business, and 152KL in the current CRAMS business.

2.Pharmaceutical Formulation Intermediates (PFIs):

Granules India Limited focused on dozens of products or only created large-volume products in limited quantities, each batch of which was processed & tested individually. Consequently, it increased the overall cost to the manufacturers and in turn the customers, which finally resulted in an increased cost of product to the end consumer. This also pulled down the overall return from the manufacturers’ ‘investments,’ especially because PFI manufacturing accounts for 80% of the total cost of a finished dosage.

3.Finished Dosages:

Granules India offers multiple finished dosage forms, comprising tablets, caplets and press-fit capsules in bulk, blister packs and bottles

Granules India Limited Subsidiary:

Granules USA, Inc: is a wholly-owned foreign subsidiary of your Company, caters to the requirements of customers in the U.S market. The Share Capital of the Company as of March 31, 2020, is ₹ 116.31 lakhs.

Granules Pharmaceuticals, Inc: is a wholly-owned foreign subsidiary of your Company located in Virginia, USA focuses on formulation R&D. The Share Capital of the Company as of March 31, 2020, is ₹ 44,359.71 lakhs.

Granules Europe Limited: Granules Europe Limited is a wholly-owned foreign subsidiary set up in the UK for focusing on marketing to European customers

Granules India Limited Joint Venture /Associate Companies

Granules-Biocause Pharmaceutical Co. Ltd: an overseas Joint Venture Company situated in China. the Company had entered into an agreement with Hubei Biocause Heilen Pharmaceutical CO., Limited., Joint Venture Partner for
sale of 33,000,000 equity shares of 1 RMB each fully paid-up held by the Company.

Granules Omnichem Private Limited: is an Indian Joint Venture Company. Upon approval of the Company had entered into Joint Venture Partner for sale of 4,28,80,967 equity shares held by the Company in Granules OmniChem Private Limited for a consideration of H 109.85 crores and this transaction was subject to the approval of the relevant regulatory authorities.

Granules India Limited Financial Highlight:

Granules India Limited Financial Statement:

Granules India Limited Cash flow:

Granules India Limited Shareholder Pattern:

• Promotors and Promotors Group: 42.04%
• Public: 57.96%
• Total: 100.00%